IN8bio(INAB)
$0.82-0.05 (-5.86%)
INAB
IN8bio stock drug pipeline
$0.82
At close:-0.05 (-5.86%)
Want to see INAB full AI Analyst Report?
IN8bio (INAB) Drug Pipeline
455 Followers
| Drug Name | Condition | Stage | Status | Study Name | Trial Start Date | Article |
|---|---|---|---|---|---|---|
| Autologous Genetically Modified Gamma-Delta T Cells, Allogeneic Genetically Modified Gamma-Delta T Cells | Glioblastoma | phase1AndPhase2 | Active Not Recruiting | A Phase 1b / 2 Drug Resistant Immunotherapy With Activated, Gene Modified Allogeneic or Autologous γδ T Cells (DeltEx) in Combination With Maintenance Temozolomide in Subjects With Recurrent or Newly Diagnosed Glioblastoma | Dec 09, 2022 | ― |
| Drug Name | Stage | Condition | Status | Study Name | Trial Start Date | Article |
|---|---|---|---|---|---|---|
| Autologous Genetically Modified Gamma-Delta T Cells, Allogeneic Genetically Modified Gamma-Delta T Cells | phase1AndPhase2 | Glioblastoma | Active Not Recruiting | A Phase 1b / 2 Drug Resistant Immunotherapy With Activated, Gene Modified Allogeneic or Autologous γδ T Cells (DeltEx) in Combination With Maintenance Temozolomide in Subjects With Recurrent or Newly Diagnosed Glioblastoma | Dec 09, 2022 | ― |
FAQ
What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases: a. Preclinical testing b. Phase 1 – Safety and dosage c. Phase 2 – Effectiveness and side effects d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does In8bio, Inc. (INAB) have in its pipeline
IN8bio INAB is currently developing the following drugs: Autologous Genetically Modified Gamma-Delta T Cells, Allogeneic Genetically Modified Gamma-Delta T Cells. These drug candidates are in various stages of clinical development as the company works toward FDA approval.
